Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Pipeline Developments & Deals by Rallybio

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Therapeutic Area filter
      Study Phase filter
        Country filter
          News Type filter
            Company filter
              refresh

              Companies By Therapeutic Area Full Screen

              Development Status Full Screen

              Rallybio

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHDH.WORLD 2.1

              Participation Not Confirmed

              Update your events

              Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1/2 Study

              Contact the Supplier

              Lead Product(s): RLYB211

              Therapeutic Area: Immunology Product Name: RLYB211

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 10, 2020

              Details:

              The Phase 1/2 study is a single-blind, placebo-controlled proof-of-concept study designed to establish the dose of RLYB211 that will rapidly clear HPA-1a positive platelets transfused to HPA-1a negative healthy male participants.

              Rallybio

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHDH.WORLD 2.1

              Participation Not Confirmed

              Update your events

              Rallybio Further Broadens Drug Development Capabilities with Addition of Róisín Armstrong, PhD

              Contact the Supplier

              Lead Product(s): RLYB211

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 28, 2020

              Details:

              Róisín Armstrong, PhD. Dr. Armstrong, a seasoned drug developer, will head the development of the Company’s lead program, RLYB211. RLYB211, a plasma-derived hyperimmune globulin, is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

              Rallybio

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHDH.WORLD 2.1

              Participation Not Confirmed

              Update your events

              Rallybio Scores $145M, Unveils Lead Rare Disease Program

              Contact the Supplier

              Lead Product(s): RLYB211

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Pivotal bioVenture Partners

              Deal Size: $145.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing May 19, 2020

              Details:

              Proceeds from the financing will be used to advance Rallybio’s current portfolio of product candidates targeting devastating rare diseases, including its lead program, RLYB211. RLYB211 is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia.

              PharmaCompass__DigitalAd